Home » PDL's Buyout of ESP Pharma: $475 Million for Drugs, Sales Team
PDL's Buyout of ESP Pharma: $475 Million for Drugs, Sales Team
Protein Design Labs has agreed to buy the hospital-focused pharmaceutical firm ESP Pharma for $300 million in cash and roughly $175 million in stock, thereby gaining marketed products, a 75-person sales force, entry into the cardiac field -- and approximately $14 million in ESP debt.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May